Funding for this research was provided by:
National Cancer Institute (R25CA134283)
National Institute of General Medical Sciences (P20GM103436, P30GM106396)
Received: 14 August 2017
Accepted: 20 March 2018
First Online: 13 April 2018
Ethics approval and consent to participate
: Personal identifiers were not transferred or transmitted along with biospecimens or demographic, lifestyle, and clinico-pathological data. De-identified samples were obtained from BioServe Biotechnologies Biorepository (Beltsville, MD). The current study met the criteria for exemption under CFR 46.101 (b) (4) from 45 CFR part 46 requirement, since it involved the use of de-identified serum samples and associated patient characteristics data. The current study on the role of de-identified serum-based miRNAs received ethics approval and waived the requirement for a signed consent under the University of Louisville’s Institutional Review Board protocol number 201.07.The study used all patient-derived cells in accordance with the University of Louisville’s Institutional Biosafety Committee under protocol (IBC 15–057). The current study predominantly used human cell lines available from the ATCC, which is a publically available repository. Any information known about the ATCC cell lines are publically available and not considered as human subjects research under HHS regulations at 45 CFR Part 46. Research that proposes the use of human cell lines available from the American Type Culture Collection or a similar repository is not considered human subjects research because the cells are publicly available and all of the information known about the cell lines (perhaps, including the donor) is also publicly available.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.